50358-63-9

Basic information

• Product Name: 5-Bromoquinoxalin-6-amine
• Synonyms: 6-Amino-5-bromoquinoxaline ,98%;5-BroMoquinoxalin-6-aMine, 6-AMino-5-broMoquinoxaline;Brimonidine Related Compound (5-Bromo-6-Aminoquinoxaline);6-AMINO-5-BROMOQUINOXALINE;5-BROMO-6-QUINOXALINAMINE;5-bromoquinoxalin-6-amine;6-Amino-5-bromoquinoxaline 98%;5-Bromo-6-aminoquinoxaline
• CAS NO: 50358-63-9
• Molecular Formula: C₈H₆BrN₃
• Molecular Weight: 224.06
• EINECS: 1592732-453-0
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Quinolines, Isoquinolines & Quinoxalines;Halides;Quinolines, Isoquinolines & Quinoxalines;Chemical Amines;Amines
• Mol File: 50358-63-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 151-153°C
• Boiling Point: 367 °C at 760 mmHg
• Flash Point: 175.8 °C
• Appearance: yellow solid
• Density: 1.744 g/cm³
• Vapor Pressure: 1.4E-05mmHg at 25°C
• Refractive Index: 1.747
• Storage Temp.: Refrigerator
• PKA: 0.33±0.30(Predicted)
• CAS DataBase Reference: 5-Bromoquinoxalin-6-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromoquinoxalin-6-amine(50358-63-9)
• EPA Substance Registry System: 5-Bromoquinoxalin-6-amine(50358-63-9)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 50358-63-9(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

Different sources of media describe the Uses of 50358-63-9 differently. You can refer to the following data:
1. A metabolite of Brimonidine.
2. Antiglaucoma agent (brimonidine tartrate ophthalmic solution) 0.15%

InChI:InChI=1/C8H6BrN3/c9-7-5(10)1-2-6-8(7)12-4-3-11-6/h1-4H,10H2

Upstream product

• 6639-87-8 6-nitroquinoxaline 
• 6298-37-9 6-aminoquinoxaline 
• 99-56-9 4-Nitrophenylene-1,2-diamine 

Relevant articles and documents

Cyclic (Alkyl)(amino)carbene Ligand-Promoted Nitro Deoxygenative Hydroboration with Chromium Catalysis: Scope, Mechanism, and Applications

Transition metal catalysis that utilizes N-heterocyclic carbenes as noninnocent ligands in promoting transformations has not been well studied. We report here a cyclic (alkyl)(amino)carbene (CAAC) ligand-promoted nitro deoxygenative hydroboration with cost-effective chromium catalysis. Using 1 mol % of CAAC-Cr precatalyst, the addition of HBpin to nitro scaffolds leads to deoxygenation, allowing for the retention of various reducible functionalities and the compatibility of sensitive groups toward hydroboration, thereby providing a mild, chemoselective, and facile strategy to form anilines, as well as heteroaryl and aliphatic amine derivatives, with broad scope and particularly high turnover numbers (up to 1.8 × 106). Mechanistic studies, based on theoretical calculations, indicate that the CAAC ligand plays an important role in promoting polarity reversal of hydride of HBpin; it serves as an H-shuttle to facilitate deoxygenative hydroboration. The preparation of several commercially available pharmaceuticals by means of this strategy highlights its potential application in medicinal chemistry.

Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines

A series of 29 new quinoxalines was synthesized and evaluated in vitro against several parasites (Leishmania donovani, Trypanosoma brucei brucei, and Trichomonas vaginalis). Several of them displayed interesting activities, and particularly four quinoxaline amides showed in vitro antileishmanial properties (IC50 less than 20 μM).

Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R1and R2each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R3, R4and R5each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain.